marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2023-Q3
added 11-14-2023
Atreca Operating Expenses 2011-2025 | BCEL
Annual Operating Expenses Atreca
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 98.7 M | 110 M | 88.9 M | 72.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 M | 72.6 M | 92.6 M |
Quarterly Operating Expenses Atreca
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.6 M | 19.8 M | 21.5 M | - | 23.3 M | 28 M | 25.7 M | - | 27.5 M | 27.1 M | 26.2 M | - | 23.4 M | 20.6 M | 21.3 M | - | 17.7 M | 19.5 M | 14.2 M | - | 9.7 M | 9.05 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.6 M | 9.05 M | 21.8 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Graybug Vision
GRAY
|
38.1 M | $ 0.44 | -11.23 % | $ 9.65 M |  USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | $ 11.3 | -10.17 % | $ 12.2 K | - |
 |
Galera Therapeutics
GRTX
|
70.6 M | $ 0.14 | -32.59 % | $ 7.61 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
106 M | $ 4.37 | -1.58 % | $ 28.1 M |  China |
 |
Axon Enterprise
AXON
|
1.18 B | $ 723.51 | -1.19 % | $ 54.8 B | USA |
 |
Caladrius Biosciences
CLBS
|
23.4 M | $ 0.43 | -16.75 % | $ 25.8 M | USA |
 |
Sorrento Therapeutics
SRNE
|
232 M | $ 0.27 | -29.58 % | $ 126 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | $ 184.71 | 0.49 % | $ 251 B |  Cayman-islands |
 |
Heron Therapeutics
HRTX
|
281 M | $ 1.2 | 3.02 % | $ 183 M | USA |
 |
ContraFect Corporation
CFRX
|
64.6 M | $ 1.47 | -5.16 % | $ 5.39 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
159 M | $ 4.93 | 1.02 % | $ 90.8 M |  Britain |
 |
Midatech Pharma plc
MTP
|
4.78 M | $ 0.29 | -18.52 % | $ 27.3 M | Britain |
 |
Advaxis
ADXS
|
22 M | $ 0.31 | -9.65 % | $ 45.9 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
27.9 M | $ 3.93 | -5.76 % | $ 99.8 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
61.4 M | $ 6.2 | - | $ 154 M | USA |
 |
Zymeworks
ZYME
|
226 K | $ 6.42 | - | $ 404 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
23 M | $ 5.72 | 5.93 % | $ 314 M | Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | $ 10.5 | - | $ 231 M | USA |
 |
Kadmon Holdings, Inc.
KDMN
|
109 M | $ 9.5 | - | $ 1.7 B | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | $ 2.58 | -4.8 % | $ 255 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
33 K | $ 0.56 | 7.23 % | $ 2.72 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | $ 0.5 | - | $ 7.46 M |  Israel |
 |
Kiromic BioPharma
KRBP
|
23.8 M | $ 3.15 | 6.61 % | $ 3.08 M | USA |
 |
Acceleron Pharma Inc.
XLRN
|
210 M | $ 179.68 | - | $ 10.9 B | USA |
 |
Albireo Pharma
ALBO
|
163 M | $ 44.15 | -0.23 % | $ 916 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
46.3 M | $ 0.32 | - | $ 23.9 M | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
61.6 M | $ 18.44 | - | $ 1.94 B | Canada |
 |
Kaleido Biosciences
KLDO
|
88.8 M | $ 0.29 | -3.69 % | $ 12.4 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
52.3 M | $ 2.19 | - | $ 105 M | USA |
 |
Humanigen
HGEN
|
70.8 M | $ 0.04 | -81.12 % | $ 4.28 M | USA |
 |
Aptinyx
APTX
|
62.6 M | $ 0.06 | -39.0 % | $ 4.57 M | USA |
 |
Tyme Technologies
TYME
|
27.2 M | $ 0.31 | 8.07 % | $ 54 M | USA |
 |
Forward Pharma A/S
FWP
|
3.39 M | $ 2.64 | -0.75 % | $ 18.7 M |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | $ 0.39 | - | $ 26.5 M | USA |
 |
Celyad Oncology SA
CYAD
|
26.2 M | $ 0.47 | - | $ 12.5 M |  Belgium |
 |
Brickell Biotech
BBI
|
14.4 M | $ 2.11 | -5.38 % | $ 6.06 M | USA |
 |
Genocea Biosciences
GNCA
|
53.7 M | $ 0.05 | -15.0 % | $ 3.04 M | USA |
 |
Codiak BioSciences
CDAK
|
92.5 M | $ 0.06 | -55.98 % | $ 2.15 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
110 M | $ 8.37 | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | $ 3.17 | 1.93 % | $ 17.4 M | USA |
 |
Novo Nordisk A/S
NVO
|
51.9 B | $ 49.14 | -0.62 % | $ 421 B | Danmark |
 |
Calithera Biosciences
CALA
|
125 M | $ 0.37 | -10.95 % | $ 876 K | USA |
 |
Forma Therapeutics Holdings
FMTX
|
174 M | $ 20.01 | - | $ 958 M | USA |
 |
Oncolytics Biotech
ONCY
|
11.5 M | $ 1.09 | -8.58 % | $ 115 M | Canada |
 |
Arena Pharmaceuticals
ARNA
|
427 M | $ 49.55 | -6.81 % | $ 3.04 B | USA |
 |
ORIC Pharmaceuticals
ORIC
|
143 M | $ 12.52 | -4.86 % | $ 873 M | USA |
 |
Sierra Oncology
SRRA
|
94.6 M | $ 54.89 | -0.05 % | $ 1.34 B | Canada |
 |
Regulus Therapeutics
RGLS
|
31.1 M | $ 8.16 | - | $ 155 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Precigen
PGEN
|
203 M | $ 4.17 | 0.72 % | $ 1.02 B | USA |